MansonJE, TostesonH, RidkerPM, SatterfieldS, HerbertP, O'ConnorGT, et al. The primary prevention of myocardial infarction. N Engl J Med1992;326(21):1406–1416.
2.
AvezumAJr, FlatherM, YusufS.Recent advances and future directions in myocardial infarction. Cardiology1994;84(6):391–407.
3.
MossAJ, BenhorinJ.Prognosis and management after a first myocardial infarction. N Engl J Med1990;322(11):743–753.
4.
HennekensCH, AlbertCM, GodfriedSL, GazianoJM, BuringJE. Adjunctive drug therapy of acute myocardial infarction-evidence from clinical trials. N Engl J Med1996;335:1660–1667.
WallinJD. β-adrenergic blockers in the hypertensive asthmatic patient?Chest1985;88(6):801–802.
8.
Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-con- trolled international trial. The MIAMI Trial Research Group. Eur Heart J1985;6(3):199–226.
9.
Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1 First Inter- national Study of Infarct Survival Col- laborative Group. Lancet1986;2(8498):57–66.
10.
SinghBN, WhitlockRML, ComberRH, WilliamsFH, HarrisEA. Effects of car- dioselective B-adrenoceptor blockade on specific airways resistance in normal sub- jects and in patients with bronchial asthma. Clin Pharmacol Ther1976;19(5, Part 1):493–501.
11.
GeorgeRB, ManochaK, BurfordJD, ConradSA, KinasewitzGT. Effects of labetolol in hypertensive patients with chronic obstructive pulmonary disease. Chest1983;83(3):457–460.
12.
SheppardD, DiStefanoS, ByrdRC, EschenbacherWL, BellV, SteckJ, LadduA.Effects of esmolol on airway function in patients with asthma. J Clin Pharmacol1986;26(3):169–174.
13.
ISIS-4: a randomised factorial trial assess- ing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet1995;345(8951):669–685.
14.
PfefferMA, BraunwaldE, MoyeLA, BastaL, BrownEJJr, CuddyTE, et al. Effect of captopril on mortality and mor- bidity in patients with left ventricular dys- function after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investi- gators. N Engl J Med1992;327(10):669–677.
15.
RavidD, LishnerM, LangR, RavidM.Angiotensin-converting enzymes and cough: a prospective evaluation in hyper- tension and in congestive heart failure. J Clin Pharmacol1994;34(11):1116–1120.
16.
PopaV.Captopril-related (and-induced?) asthma. Am Rev Respir Dis1987;136(4):999–1000.
LacourciereY, LefebvreJ, NakhleG, Fai-sonEP, SnavelyDB, NelsonEB. Asso- ciation between cough and angiotensin- converting enzyme inhibitors versus angiotensin II antagonists: the design of a prospective, controlled study. J Hyper- tens1994;12(Suppl, 2):S49–S53.
20.
FarbA, TangAL, BurkeAP, SessumsL, LiangY, VermaniR.Sudden coronary death. Frequency of active coronary lesions, inactive coronary lesions, and myocardial infarction. Circulation1995;92(7):1701–1709.
21.
DalyLE, HickeyN, GrahamIM, MulcahyR.Predictors of sudden death up to 18 years after a first attack of unstable angina or myocardial infarction. Br Heart J1987;58(6):567–571.
22.
SchafferWA, CobbLA. Recurrent ven- tricular fibrillation and modes of death in survivors of out-of-hospital ventricular fib- rillation. N Engl J Med1975;293(6):259–262.
23.
MukharjiJ, RudeRE, PooleWK, GustafsonN, ThomasLJJr, StraussHW, et al, and the MILIS Study Group. Risk factors for sudden death after acute myocardial infarction: two-year follow- up. Am J Cardiol1984;54(1):31–36.
24.
EchtDS, LiebsonPR, MitchellLB, PetersRW, Obias-MannoD, BarkerAH, et al, and the CAST Investigators. Mortality and morbidity in patients receiving encaina- mide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med1991;324(12):781–788.
25.
SteinMJ, DemarcoT, GamsuG, Fink-beinerW, GoldenJA. Computed tomog- raphy: pathologic correlation in lung dis- ease due to tocainide. Am Rev Respir Dis1988;137(2):458–460.
26.
BeroCJ, RihnTL. Possible association of pulmonary fibrosis with mexiletine. DICP Ann Pharmacothera1991;25(12):1329–1331.
27.
Effect of the antiarrhythmic agent mori- cizine on survival after myocardial infarc- tion. The Cardiac Arrhythmia Suppression Trial II Investigators. N Engl J Med1992;327(4):227–233.
28.
WaldoAL, CammAJ, deRuyterH, Fried-manPL, MacNeilDJ, PaulsJF, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Lancet1996;348(9019):7–12.
29.
PodridPJ. Amiodarone: reevaluation of an old drug. Ann Intern Med1995;122(9):689–700.
30.
TeoKK, YusufS, FurbergCD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled tri- als. JAMA1993;270(13):1589–1595.
31.
WeinbergBA, MilesWM, KleinLS, BolanderJE, DusmanRE, StantonMS, et al. Five-year follow-up of 589 patients treated with amiodarone. Am Heart J1993;125(1):109–120.
32.
DusmanRE, StantonWS, MilesWM, KleinLS, ZipesDP, FinebergNS, HegerJJ. Clinical features of amiodarone-induced pulmonary toxicity. Circulation1990;82(1):51–59.
33.
WoodDL, OsbornML, RookeJ, HolmesDRJr. Amiodarone pulmonary toxicity: report of two cases associated with rapidly progressive fatal adult respiratory distress syndrome after pulmonary angiography. Mayo Clin Proc1985;60(9):601–603.
BlomgrenSE, CondemiJJ, VaughanJH. Procainamide-induced lupus erythe- matosus. Am J Med1972;52(3):338–348.
36.
WoosleyRL, DrayerDE, ReidenbergMM, NiesAS, CarrK, OatesJA. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med1978;298(21):1157–1159.
37.
PatronoC.Aspirin as an antiplatelet drug. N Engl J Med1994;330(18):1287–1294.
38.
IsraelE, FischerAR, RosenbergMA, LillyCM, CalleryJC, ShapiroJ, et al. The piv- otal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis1993;148(6, Part 1):1447–1451.
